The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Some stimulatory receptors of the innate immune system, such as the NKG2D receptor (also called KLRK1) expressed by natural killer cells and activated CD8(+)T cells, recognize self-molecules that are upregulated in diseased cells by poorly understood mechanisms. Here we show that mouse and human NKG2D ligands are upregulated in non-tumour cell lines by genotoxic stress and stalled DNA replication, conditions known to activate a major DNA damage checkpoint pathway initiated by ATM (ataxia telangiectasia, mutated) or ATR (ATM- and Rad3-related) protein kinases. Ligand upregulation was prevented by pharmacological or genetic inhibition of ATR, ATM or Chk1 (a downstream transducer kinase in the pathway). Furthermore, constitutive ligand expression by a tumour cell line was inhibited by targeting short interfering RNA to ATM, suggesting that ligand expression in established tumour cells, which often harbour genomic irregularities, may be due to chronic activation of the DNA damage response pathway. Thus, the DNA damage response, previously shown to arrest the cell cycle and enhance DNA repair functions, or to trigger apoptosis, may also participate in alerting the immune system to the presence of potentially dangerous cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, genomic damage—a common cause of cellular senescence—induces expression of the membrane-bound ligands for the major natural killer cell receptor NKG2D (140).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [140]
The cited source says what the claim attributes to it.
In the citing paper
“other evidence indicates that the immune system's recognition of tumour cells might require the continuous activation of the DDR pathway 13”
From The common biology of cancer and ageing (2007) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further, DNA damage or activation of oncogenes can induce cellular senescence, through a pathway that relies, in part, on the secretion of pro-inflammatory cytokines such as insulin-like growth factor binding protein-7 (IGFBP7)32 and IL-633, and on the secretion of CXC-chemokine ligand 8 (CXCL8) and other chemokines 33,34, as well as on the expression of the CXCL8 receptor CXC-chemokine receptor 2”
From Immunogenic and tolerogenic cell death (2009) · cites this paper as [32]
Experimental — accuracy not yet measuredIn the citing paper
“These findings are consistent with previous studies suggesting that NKG2D ligands are induced by a variety of other stimuli, including E2F transcription factors, PI3 kinase, Ras oncogene signaling, and an activated DNA damage response (Gasser et al., 2005; Tokuyama et al., 2011; Jung et al., 2012).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Gasser et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: p73α Regulation by Chk1 in Response to DNA Damage
Gonzalez, S., Prives, C., & Cordon-Cardo, C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8161-8171.2003 · Cited by 75
RetractedDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Cell cycle checkpoint signaling through the ATM and ATR kinases
Abraham, R. T. (2001) · Genes & Development · doi:10.1101/gad.914401 · Cited by 1,966
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
Roles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Self-citation(1999) · PubMed · Cited by 1,030
ATR disruption leads to chromosomal fragmentation and early embryonic lethality
Brown, E. J., & Baltimore, D. (2000) · Genes & Development · doi:10.1101/gad.14.4.397 · Cited by 951
Self-citation
Cited by
Items 501–600 of 1,000
Nausch, N., Florin, L., Hartenstein, B., Angel, P. E., Schorpp‐Kistner, M., & Cerwenka, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.7 · Cited by 62
“(15) reported regulation of mouse and human NKG2D ligands by a DNA damage pathway.”
BackgroundSkin immune surveillance by T cells—A new order?
Strid, J., Tigelaar, R. E., & Hayday, A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.03.002 · Cited by 60
Song, H., Park, H.-J., Kim, J., Park, G., Kim, Y.-S., Kim, S. M., Kim, D., Seo, S. K., Lee, H.-K., Cho, D.-H., et al. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.01.009 · Cited by 54
Amin, P. J., & Shankar, B. S. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.026 · Cited by 53
Radiotherapy in Combination With Cytokine Treatment
Palata, O., Podzimkova, N., Nedvedova, E., Umprecht, A., Sadilkova, L. K., Jelinkova, L. P., Špíšek, R., & Adkins, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00367 · Cited by 55
“• in cancer cells to enable recognition by cytolytic T cells (35, 36) Conversion of ATP”
BackgroundCellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
Eagle, R. A., Flack, G., Warford, A., Martínez-Borra, J., Jafferji, I., Traherne, J. A., Ohashi, M., Boyle, L. H., Barrow, A. D., Caillat‐Zucman, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004503 · Cited by 59
“Activation of DNA damage pathways during tumour development has been reported to be a central mechanism leading to NKG2D ligand expression [17].”
BackgroundKarimi, M. A., Bryson, J. L., Richman, L. P., Fesnak, A. D., Leichner, T. M., Satake, A., Vonderheide, R. H., Raulet, D. H., Reshef, R., & Kambayashi, T. (2015) · Blood · doi:10.1182/blood-2015-02-629006 · Cited by 52
Self-citationDacarbazine in Melanoma: From a Chemotherapeutic Drug to an Immunomodulating Agent
Ugurel, S., Paschen, A., & Becker, J. C. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.341 · Cited by 52
Wahle, J. A., Paraiso, K. H. T., Kendig, R. D., Lawrence, H. R., Chen, L., Wu, J., & Kerr, W. G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8009 · Cited by 52
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
Alistar, A. T., Chou, J. W., Nagalla, S., Black, M. A., D¿Agostino, R., & Miller, L. D. (2014) · Genome Medicine · doi:10.1186/s13073-014-0080-8 · Cited by 54
“Alternatively, chemotherapeutic agents are known to exert a variety of other immunostimulatory effects, including: 1) induction of MHC class I expression and subsequent presentation of tumor antigens [67]; 2) increased expression of ligands that stimulate tumor-reactive activation of NK and cytotoxic T cells [68,69];…”
BackgroundExploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A. D., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 55
“to promote elimination by NK cells [171].”
Tokuyama, M., Lorin, C., Delebecque, F., Jung, H., Raulet, D. H., & Coscoy, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002265 · Cited by 51
“These fibroblasts have previously been used to demonstrate RAE-1 induction upon activation of the DNA damage response [18].”
BackgroundMethodSelf-citationNatural killer cells in cancer immunotherapy
Wang, D., Dou, L., Sui, L., Xue, Y., & Xu, S. (2024) · MedComm · doi:10.1002/mco2.626 · Cited by 58
“143,144 Thus, the pharmacological or genetic inhibition of ATR, ATM, or Chk1 could suppress the downstream mediators of these pathways, and then prevent the upregulation of the NKG2D ligands.”
BackgroundCancer Stem Cell markers: Symphonic masters of chemoresistance and immune evasion
Sarabia-Sánchez, M. Á., Tinajero-Rodríguez, J. M., Ortíz-Sánchez, E., & Alvarado-Ortiz, E. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123015 · Cited by 54
Systemic DNA damage responses: organismal adaptations to genome instability
Ermolaeva, M. A., & Schumacher, B. (2014) · Trends in Genetics · doi:10.1016/j.tig.2013.12.001 · Cited by 50
“ATM signaling upon DNA damage can indeed induce expression of the ligand for the natural killer group 2 member D (NKG2D) receptor that is present on natural killer cells [33].”
Backgroundde Menthon, M., Lambert, M., Guiard, E., Tognarelli, S., Bienvenu, B., Karras, A., Guillevin, L., & Caillat‐Zucman, S. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30355 · Cited by 51
Cui, J., Li, L., Wang, C., Jin, H., Cheng, Y., Wang, Y., Li, D., Tian, H., Niu, C. S., Wang, G., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.03.605 · Cited by 51
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Cifaldi, L., Locatelli, F., Marasco, E., Moretta, L., & Pistoia, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.002 · Cited by 57
El‐Deeb, N. M., El-Adawi, H. I., El-Wahab, A. E. A., Haddad, A. M., Enshasy, H. A. E., He, Y.-W., & Davis, K. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00165 · Cited by 51
“Also, the genotoxic stress of cancer cells has abilities to increase tumor cell lysis sensitivity that mediated by NKG2DL expression induction of NK cells through DDR activation (Gasser et al., 2005; Cerboni et al., 2014).”
BackgroundBeyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation
Nathansen, J., Meyer, F., Müller, L., Schmitz, M., Borgmann, K., & Dubrovska, A. (2021) · Cancers · doi:10.3390/cancers13194818 · Cited by 54
Immuno-regulatory antibodies for the treatment of cancer
Honeychurch, J., Cheadle, E. J., Dovedi, S. J., & Illidge, T. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036737 · Cited by 53
“Standard-of-care treatments such as chemotherapy and radiotherapy (RT) can modulate the tumor cell phenotype to increase antigenicity [2], promote immune-mediated killing [3] and trigger immunogenic cell death associated with the release of damage-associated molecular patterns, leading to enhanced acquisition and proc…”
BackgroundDevelopment of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
Bai, R., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890166 · Cited by 52
Hak, C. C. W., Rullan, A., Patin, E. C., Pedersen, M., Melcher, A. A., & Harrington, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971959 · Cited by 51
“In addition, conditions that activate ATM and ATR as part of DDR may also participate in regulating the innate immune system and alert it to potentially ‘dangerous’ tumour cells (70).”
BackgroundTumor cell recognition by the NK cell activating receptor NKG2D
Bryceson, Y. T., & Ljunggren, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838833 · Cited by 53
Novel immune modulators used in hematology: impact on NK cells
Krieg, S., & Ullrich, E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00388 · Cited by 55
“Interactions of NKG2D with chemically induced MICB significantly enhanced the killing capacity of a NK cell line upon pre-treatment with decitabine, most likely due to DNA damage and promotor DNA demethylation (Gasser et al., 2005; Tang et al., 2008).”
BackgroundChen, J., Huang, X., Huang, G., Chen, Y., Chen, L., & Song, H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.1116 · Cited by 51
“It could increase the susceptibility of tumor cells to the lysis by lymphocytes through upregulating the expression of the NKG2D ligand (NKG2DL) or Fas on tumor cells.(29,30) Our previous study has also demonatrated that DDP could deplete the splenic and intratumoral Treg cells to guarantee the success of CIK therapy…”
Zhang, T., & Sentman, C. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201314 · Cited by 53
“DNA pathways initiated by ATM or ATR protein kinases have been shown to play important roles in upregulation of NKG2D ligands (17).”
BackgroundPhosphatidylinositol 3-Kinase Activation Is Required To Form the NKG2D Immunological Synapse
Giurisato, E., Cella, M., Takai, T., Kurosaki, T., Feng, Y., Longmore, G. D., Colonna, M., & Shaw, A. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01477-07 · Cited by 50
“NKG2D recognizes ligands that are often induced due to the consequences of cellular stress, such as DNA damage, tumors, and viral infections (22).”
BackgroundGuo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 53
“In fact, it has been demonstrated that DNA damage and/or p53 activation, either dependent or independent of each other, upregulate the expression of NKG2D ligand such as ULBP2, greatly enhance NK mediated tumor elimination, and alter the antigen presentation capacity of tumors and stromal cells toward immune-stimulati…”
BackgroundSelecting the best haploidentical donor
McCurdy, S. R., & Fuchs, E. J. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.08.001 · Cited by 49
“lead to tumor directed killing [59–61].”
Inflammation, a significant player of Ataxia–Telangiectasia pathogenesis?
Zaki‐Dizaji, M., Akrami, S. M., Azizi, G., Abolhassani, H., & Aghamohammadi, A. (2018) · Inflammation Research · doi:10.1007/s00011-018-1142-y · Cited by 50
The NKG2D axis: an emerging target in cancer immunotherapy
Lazarova, M., & Steinle, A. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1580693 · Cited by 47
Huergo-Zapico, L., González, A. P., Contesti, J., González, E., López‐Soto, A., Fernández-Guizán, A., Acebes‐Huerta, A., Toyos, J. R. D. L., López‐Larrea, C., Groh, V., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1195-z · Cited by 55
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
Di Modica, M., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G. V., Generali, D., Balsari, A., Triulzi, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6353 · Cited by 47
“It binds multiple ligands, including MHC class I chain-related A (MICA), MICB and several UL-16 binding proteins (ULBPs), which are induced after cellular stress [12] and are the most common ligands for NK cell receptors in breast carcinomas together with DNAM-1 ligands [13].”
BackgroundRadiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 49
“While doubt may arise as to whether HLA molecules upregulated upon irradiation may inhibit NK cell activity [53], there seems to be indications of stimulatory NKG2D ligands being simultaneously upregulated [111].”
BackgroundLocal tumour ablative therapies: Opportunities for maximising immune engagement and activation
O'Brien, M. A., Power, D. G., Clover, A. J. P., Bird, B., Soden, D. M., & Forde, P. F. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.005 · Cited by 56
“The NKG2D ligands can be induced on tumour cells through DNA damage [20] and other stimuli,”
BackgroundGenomic instability as a driver and suppressor of anti-tumor immunity
Requesens, M., Foijer, F., Nijman, H. W., & de Bruyn, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462496 · Cited by 51
“Murine and human NKG2D and DNAM-1 ligands are upregulated by genotoxic stress and stalled DNA replication, both known to activate the DNA damage response (4, 220 – 222).”
Senescence, NK cells, and cancer: navigating the crossroads of aging and disease
Gergues, M., Bari, R., Koppisetti, S., Gosiewska, A., Kang, L., & HARIRI, R. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565278 · Cited by 52
“This not only prevents the ligands from engaging with their cognate-activating receptors on NK cells but may also lead to the depletion of these ligands in the microenvironment (211).”
Deguine, J., Bréart, B., Lemaître, F., & Bousso, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202065 · Cited by 51
“Indeed, ligands for this receptor are often overexpressed on transformed cells because their expression can be induced by oncogenes (11) or through the DNA damage response (12).”
BackgroundLu, S., Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Li, Z., & Wu, J. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0845 · Cited by 47
“This DNA repair response also triggers systemic checkpoint by upregulating NKG2D ligand, predominantly MIC, expression to alert the immune system to eliminate abnormal cells (1, 3).”
BackgroundIntratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Fritzell, S., Sandén, E., Eberstål, S., Visse, E., Darabi, A., & Siesjö, P. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1449-z · Cited by 49
Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 48
Kwong, K. Y., Baskar, S., Zhang, H., Mackall, C. L., & Rader, C. M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.008 · Cited by 47
Singh, S. V., Ajay, A. K., Mohammad, N., Malvi, P., Chaube, B., Meena, A. S., & Bhat, M. K. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.292 · Cited by 46
“From the pharmacological point of view, MMC is effective at relatively low dose with minimal organ-associated toxicity(11) and it has been shown to activate innate immunity.(12) However, therapeutic efficacy of MMC principally depends on other drug types in combination therapy.”
BackgroundNoci, V. L., Tortoreto, M., Gulino, A., Storti, C., Bianchi, F., Zaffaroni, N., Tripodo, C., Tagliabue, E., Balsari, A., & Sfondrini, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1040214 · Cited by 46
Natural killer cell-based therapies
Romagné, F., & Vivier, É. (2011) · F1000 Medicine Reports · doi:10.3410/m3-9 · Cited by 46
“some inhibitors, such as bortezomib, which is now registered for the treatment of multiple myeloma, have also been shown to induce NK-stimulatory ligands [44,45].”
BackgroundTrabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Cucè, M., Cantafio, M. E. G., Siciliano, M. A., Riillo, C., Caracciolo, D., Scionti, F., Staropoli, N., Zuccalà, V., Maltese, L., Vito, A. D., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0714-9 · Cited by 47
“Indeed, besides participating in cell cycle control and induction of apoptosis, DDR works as a sensor for cellular stress or transformation, inducing recognition by the immune system [5, 6].”
BackgroundA Role for Host Activation-Induced Cytidine Deaminase in Innate Immune Defense against KSHV
Bekerman, E., Jeon, D., Ardolino, M., & Coscoy, L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003748 · Cited by 49
“One of the downstream consequences of such responses is the upregulation of stimulatory NK cell ligands [38].”
BackgroundHistone deacetylase regulation of immune gene expression in tumor cells
Khan, A. N. H., & Tomasi, T. B. (2007) · Immunologic Research · doi:10.1007/s12026-007-0085-0 · Cited by 48
“In this scenario, NKG2DL also could be induced by the ATM/ATR DNA damage pathway in cancer cells [54].”
BackgroundXu, X., Rao, G., Gaffud, M. J., Ding, H. G., Maki, G., Klingemann, H.-G., Groh, V., Spies, T. A., Caillat‐Zucman, S., Gattuso, P., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0492 · Cited by 46
An epigenetic vaccine model active in the prevention and treatment of melanoma
Khan, A. N. H., Magner, W. J., & Tomasi, T. B. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-64 · Cited by 47
“Finally, HDACi modulates DNA damage (ATM/ ATR) [35] and MAPK pathways [51] and could therefore serve as an intracellular adjuvant, which have been shown to enhance DC vaccine potential [34].”
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 46
Kim, H. L., & Seo, Y. R. (2012) · Oncology Reports · doi:10.3892/or.2012.2057 · Cited by 45
“MHC class I polypeptide-related sequence A (MICA) is overexpressed as the result of a DNA damage response involving the ATM (ataxia telangiectasia mutated) and the ATR (ATM- and Rad3-related) protein kinases (32).”
BackgroundMICA Variant Promotes Allosensitization after Kidney Transplantation
Tonnerre, P., Gérard, N., Chatelais, M., Poli, C., Allard, S., Cury, S., Bressollette‐Bodin, C., Cesbron‐Gautier, A., & Charreau, B. L. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012080814 · Cited by 47
Espinoza, J. L., & Minami, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00052 · Cited by 46
“Another consequence of DDR and ATM/ATR activation is the induction of cell stress molecules that are proteins expressed on the surface of damaged cells (18, 19).”
BackgroundBasher, F., Dhar, P., Wang, X., Wainwright, D. A., Zhang, B., Sosman, J., Ji, Z., & Wu, J. D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00896-0 · Cited by 43
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
de Jong, F. C., Rutten, V. C., Zuiverloon, T. C. M., & Theodorescu, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062800 · Cited by 50
“Radiation may have immune-mediated distant effects, termed the abscopal effect, which refers to regression of non-irradiated lesions located elsewhere than the primary radiated site [62].”
BackgroundManipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response
Jonjić, S. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00085 · Cited by 50
“Both human and mouse cells upregulate NKG2D ligands following treatment with DNA-damaging agents (Gasser et al., 2005) that activate a major DNA damage pathway initiated by ATM (Ataxia telangiectasia, mutated) or ATR (ATM- and Rad3-related) protein kinases (Bartkova et al., 2005; Gorgoulis et al.,…”
BackgroundPerforin-mediated suppression of B-cell lymphoma
Bolitho, P., Street, S. E. A., Westwood, J. A., Edelmann, W., MacGregor, D. P., Waring, P., Murray, W. K., Godfrey, D. I., Trapani, J. A., Johnstone, R. W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809008106 · Cited by 46
“Clearly, the precedent exists, with certain DNA damage pathways leading to stress ligand expression by transformed cells and recognition by effector lymphocytes (41).”
BackgroundNK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
Fregni, G., Perier, A., Avril, M., & Caignard, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18312 · Cited by 44
Cancer Immunosurveillance: NKG2D Breaks Cover
Ljunggren, H. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.007 · Cited by 44
“A DNA-damage pathway regulates NKG2D ligand expression (Gasser et al., 2005).”
BackgroundGasser, S., Zhang, W. Y. L., Tan, N. Y., Tripathi, S., Suter, M. A., Chew, Z. H., Khatoo, M., Ngeow, J. Y. Y., & Cheung, F. S. G. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.001 · Cited by 46
Self-citationT Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
Huang, W., Easom, N. J. W., Tang, X.-Z. E., Gill, U. S., Singh, H., Robertson, F. P., Chang, C., Trowsdale, J., Davidson, B. R., Rosenberg, W. M., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601313 · Cited by 44
“NKG2DL expression on a cell can be regulated at multiple levels, including the ATM/ ATR DNA damage response driving transcription (22, 28, 50, 52) and activation of the epidermal growth factor receptor stabilizing at the posttranscriptional level (24).”
BackgroundImmunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review
Takahashi, J., & Nagasawa, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239324 · Cited by 48
Murine NKG2D ligands: “Double, double toil and trouble”
Samarakoon, A., Chu, H., & Malarkannan, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.035 · Cited by 44
“DNA damage pathway that is initiated by ataxia telangiectasia mutated (ATM) or ataxia telegiectasia Rad3-related (ATR) kinases has been implicated in the expression of murine NKG2D ligands(Gasser et al., 2005).”
BackgroundSiew, Y.-Y., Neo, S.-Y., Yew, H.-C., Lim, S.-W., Ng, Y.-C., Lew, S.-M., Seetoh, W.-G., Seow, S.-V., & Koh, H. (2015) · International Immunology · doi:10.1093/intimm/dxv041 · Cited by 45
Natural killer cells in immunodefense against infective agents
Zucchini, N., Crozat, K., Baranek, T., Robbins, S. H., Altfeld, M. A., & Dalod, M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.867 · Cited by 44
Lu, X., Ohata, K., Kondo, Y., Espinoza, J. L., Qi, Z., & Nakao, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01439.x · Cited by 46
Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki, T., Onishi, H., & Katano, M. (2012) · PubMed · Cited by 52
Kaur, K., Chang, H.-H., Topchyan, P., Cook, J., Barkhordarian, A., Eibl, G., & Jewett, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01229 · Cited by 44
The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction
Market, M., Baxter, K. E., Angka, L., Kennedy, M. A., & Auer, R. C. (2018) · Cancers · doi:10.3390/cancers11010002 · Cited by 44
Inflammatory signaling in genomically instable cancers
Talens, F., & van Vugt, M. A. T. M. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1638192 · Cited by 43
“Also, STING activation in tumor cells as a result of DNA damage and ensuing cytoplasmic DNA triggers the expression of NKG2D receptor ligands, which promotes NK cell-dependent tumor cell killing [114,115].”
BackgroundSegura‐Bayona, S., Villamor-Payà, M., Attolini, C. S., König, L. M., Sanchiz-Calvo, M., Boulton, S. J., & Stracker, T. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107983 · Cited by 50
“However, we cannot exclude a potential contribution of RS, micronuclei, ERVs, or reverse-transcribed transcripts to the IFN response (Coquel et al., 2018; De Cecco et al., 2019; Gasser et al., 2005; Heijink et al., 2019; Reisländer et al., 2019).”
BackgroundImpact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 47
“stress ligands for NKG2D, an activatory co-receptor found on innate and cytotoxic lymphocytes [159].”
BackgroundSchierle, S., & Merk, D. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1643322 · Cited by 43
Emerging Treatment Paradigms in Radiation Oncology
Le, Q., Shirato, H., Giaccia, A. J., & Koong, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1191 · Cited by 44
“Moreover, radiotherapy can increase the expression of death receptors (54, 55), MHC class I proteins (56, 57), costimulatory molecules (58), and stress-induced ligands (59, 60) on tumor cells that enhance their recognition and killing by T lymphocytes.”
BackgroundZhang, Q., Rahim, M. M. A., Allan, D., Tu, M. M., Belanger, S., Abou-Samra, E., Ma, J., Sekhon, H. S., Fairhead, T., Zein, H. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050561 · Cited by 42
“The best characterized examples of receptors include members of the Ly49 family, which bind to class I MHC (MHC-I) and inhibit NK cell responses, and the NKG2D receptor, which binds to MHC-related ligands that are induced following genotoxic or infectious stress, resulting in the activation of NK cells, in turn leadin…”
BackgroundAndersson, K., Williams, G. S., Davis, D., & Höglund, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200636693 · Cited by 55
Williams, L. R., Quinn, L. L., Rowe, M., & Zuo, J. (2015) · Journal of Virology · doi:10.1128/jvi.01932-15 · Cited by 42
“NKG2D ligands are known to be upregulated in response to a number of stress signals, including DNA damage (36), raising the possibility that upregulation of NKG2D ligands by BZLF1 may be an indirect result of induced DNA damage.”
BackgroundImmunosurveillance and therapy of multiple myeloma are CD226 dependent
Guillerey, C., de Andrade, L. F., Vučković, S., Miles, K. M., Ngiow, S. F., Yong, M. C. R., Teng, M. W. L., Colonna, M., Ritchie, D. S., Chesi, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82646 · Cited by 46
Gannagé, M., Buzyn, A., Bogiatzi, S. I., Lambert, M., Soumelis, V., Cortivo, L. D., Cavazzana, M., Brousse, N., & Caillat‐Zucman, S. (2008) · Transplantation · doi:10.1097/tp.0b013e31816691ef · Cited by 41
“These results extend recent data showing up-regulation of NKG2D-L by genotoxic stress in human foreskin fibroblasts (3), and suggest that both conditioning regimen and TNF- release can induce NKG2D-L expression in host skin and intestinal tissues during aGVHD.”
BackgroundResultSon, C., Keum, J.-H., Yang, K., Nam, J., Kim, M., Kim, S., Kang, C., Oh, S., Kim, C., Park, Y.-S., et al. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-49 · Cited by 41
“Although it has been reported that ionizing radiation can induce NKG2D ligands on cancer cells by activating the ATM-ATR pathway [9], the precise regulatory mechanism involved is unclear.”
BackgroundMethodInfluentialThe Immunology of Ablative Radiation
Burnette, B., & Weichselbaum, R. R. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.009 · Cited by 44
DNA damage, tumor mutational load and their impact on immune responses against cancer
Liontos, M., Anastasiou, I. P., Bamias, A., & Dimopoulos, M. A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.11 · Cited by 43
“showed that triggering of DNA damage response apical kinases ATM and ATR leads to transcriptional upregulation of natural-killer group 2, member D (NKG2D) ligands (19) belonging to the ULBP and MIC family molecules.”
BackgroundThe anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancer
Walshaw, R. C., Honeychurch, J., Illidge, T., & Choudhury, A. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.172 · Cited by 43
Sojoodi, M., Wei, L., Erstad, D. J., Yamada, S., Fujii, T., Hirschfield, H., Kim, R. S., Lauwers, G. Y., Lanuti, M. D., Hoshida, Y., et al. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0383 · Cited by 43
“TWNT4 cells also increase the expression of immunosurveillance cytokines (IL6 and IL8), which are known to induce recruitment of natural killer cells, regulatory T lymphocytes, and macrophages to remove matrix debris and activated HSC (45, 47).”
BackgroundCharacterization and IL-15 dependence of NK cells in humanized mice
Pek, E. A., Chan, T., Reid, S., & Ashkar, A. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.04.008 · Cited by 41
Kuba, A., & Raida, L. (2018) · Mediators of Inflammation · doi:10.1155/2018/9451950 · Cited by 45
“As mentioned previously, also the expression of membrane-bound ligands for NKG2D by senescent cells after DNA damage corresponds with GVHD-related NKG2D expression by CD8+ T-cells in murine models of HSCT [113].”
BackgroundZhang, L., Zhang, Y., Wang, X., Zhou, Y., Qi, J., Gu, L., Zhao, Q., Yu, R., & Zhou, X. (2023) · Small · doi:10.1002/smll.202301439 · Cited by 43
Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored
de la Cruz‐Merino, L., Illescas-Vacas, A., pez, A. G.-L., Barco-Sánchez, A., & MÃguez-Sánchez, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00102 · Cited by 42
Käsmann, L., Eze, C., Taugner, J., Roengvoraphoj, O., Dantes, M., Schmidt-Hegemann, N.-S., Schiopu, S., Belka, C., & Manapov, F. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01595-3 · Cited by 45
“RT also increases natural killer group 2 member D (NKG2D) ligands in NSCLC which aids in tumour cell killing by interacting with NKG2D receptors on NK, NKT and γδ T cells [35, 36].”
BackgroundCytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics
Říhová, B., Kovář, L., Kovář, M., & Hovorka, O. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.10.006 · Cited by 40
Ratikan, J. A., Micewicz, E. D., Xie, M. W., & Schaue, D. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.031 · Cited by 41
“Of note, DNA damage and ATM activation can drive ligands for another innate receptor, namely the NKG2D receptor that is particularly relevant for NK cells activity [57] and it is easy to extrapolate this and envision a similar scenario for a radiation-driven TLR activation.”
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Dulphy, N., Chrétien, A.-S., Khaznadar, Z., Fauriat, C., Nanbakhsh, A., Caignard, A., Chouaïb, S., Olive, D., & Toubert, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00094 · Cited by 44
“Importantly, ataxia telangiectasia, mutated (ATM), and ATMand Rad3-related (ATR) protein kinases activation as a response to DNA damage can stimulate NKG2D-ligands (NKG2D-L) surface expression (42).”
BackgroundLangerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis
Ortner, D., Tripp, C. H., Komenda, K., Dubrac, S., Zelger, B., Hermann, M., Doppler, W., Tymoszuk, P., Boon, L., Clausen, B. E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1260215 · Cited by 41
“These proteins, namely H60, Mult-1 and Rae-1, indicate cell transformation and mark cells for clearance by the immune system.(4,5,27) The increased expression of the two NKG2D-L H60 and Rae-1 has been described in pre-cancerous skin as well as papilloma and carcinoma.”
BackgroundOkita, R., Wolf, D., Yasuda, K., Maeda, A., Yukawa, T., Saisho, S., Shimizu, K., Yamaguchi, Y., Oka, M., Nakayama, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139809 · Cited by 39
“It is reported that the expression of NKG2D ligands is regulated by DNA stress-induced ATM-ATR signaling [15], while other groups including us reported that oncogenes BCL/ABL and HER3 also regulated the expression of NKG2D ligands in transformed cells via mainly PI3K-AKT pathway [16, 17].”
BackgroundResultInfluentialNegative Regulation of NKG2D Expression by IL-4 in Memory CD8 T Cells
Ventre, E., Brinza, L., Schicklin, S., Mafille, J., Coupet, C., Marçais, A., Djebali, S., Jubin, V., Walzer, T., & Marvel, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102954 · Cited by 39
“that are not expressed by healthy tissues, but are rapidly induced in stressed cells such as tumor cells (37) or cells infected by viruses or bacteria (38, 39).”
BackgroundProtein disulfide isomerases are antibody targets during immune-mediated tumor destruction
Fonseca, C., Soiffer, R. J., Ho, V. T., Vanneman, M. W., Jinushi, M., Ritz, J., Neuberg, D. S., Stone, R. M., DeAngelo, D. J., & Dranoff, G. (2008) · Blood · doi:10.1182/blood-2007-09-114157 · Cited by 42
Chacon, J. A., Schutsky, K., & Powell, D. J. (2016) · Vaccines · doi:10.3390/vaccines4040043 · Cited by 43
“NKG2D is a critical receptor for the recognition and elimination of aberrant cells, and its ligands are induced during cellular stress, including infection, malignant transformation or administration of chemotherapeutics [69,95,96].”
BackgroundSpironolactone and XPB: An Old Drug with a New Molecular Target
Gabbard, R. D., Hoopes, R. R., & Kemp, M. G. (2020) · Biomolecules · doi:10.3390/biom10050756 · Cited by 43
“Nonetheless, the genomic stress response kinases ATM and ATR had previously been reported to be required for NKG2DL expression [51], and Leung et al.”
Background
Metadata
- Authors
- Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2005-07-03
- Volume
- 436
- Issue
- 7054
- Pages
- 1186-1190
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC1352168
- OpenAlex
- W1969464492
- Cited by
- 1,308
- References
- 28
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 26 · 2023: 51 · 2022: 57 · 2021: 60 · 2020: 72 · 2019: 62 · 2018: 62 · 2017: 64 · 2016: 63 · 2015: 71 · 2014: 85 · 2013: 74 · 2012: 68
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Prostate Cancer Foundation
- National Institutes of Health
- National Cancer Institute (R01CA093678)
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- NKG2D, NKG2D ligands, DNA damage response, innate immunity, ATM kinase, ATR kinase, Chk1, genotoxic stress, natural killer cells, CD8+ T cells, cancer cell lines, siRNA
- MeSH terms
- Checkpoint Kinase 1, Animals, Cell Transformation, Neoplastic, DNA Damage, DNA Replication, Fibroblasts, Humans, Immune System, Immunity, Innate, Kinetics, Ligands, Mice, Inbred C57BL, Phosphorylation, Protein Kinases, Receptors, Immunologic, Up-Regulation, Aphidicolin, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cell Line, Tumor, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.